Ultragenyx Pharmaceutical Inc. (RARE) Financials

RARE Assets vs Liabilities

DateAssetsLiabilities
2024-03-31 1.3 billion 1.2 billion
2023-12-31 1.5 billion 1.2 billion
2023-09-30 1.2 billion 1.2 billion
2023-06-30 1.3 billion 1.2 billion

RARE Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2024-03-31 -203.9 million ?
2023-12-31 -85.5 million 33.7 million
2023-09-30 -121.6 million 34.9 million
2023-06-30 -132.6 million 34.7 million

RARE Net Income

No data available :(

RARE Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2024-03-31 418.4 million - -
2023-12-31 777.1 million - 43.2 million
2023-09-30 524.2 million - 46.6 million
2023-06-30 552.0 million - 25.7 million

RARE Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2024-03-31 84.3 million
2023-12-31 81.1 million
2023-09-30 71.7 million
2023-06-30 70.9 million

RARE Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2024-03-31 13.2 million 169.6 million - -
2023-12-31 1.6 million 160.6 million 76.8 million -
2023-09-30 3.7 million 157.2 million 74.9 million -
2023-06-30 16.4 million 164.9 million 81.4 million -

RARE Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2024-03-31 108.8 million 26.4 million
2023-12-31 127.4 million 12.1 million
2023-09-30 98.1 million 11.0 million
2023-06-30 108.3 million 9.9 million

RARE

Price: $43.01

52 week price:
31.52
54.98

Earnings Per Share: -8.25 USD

P/E Ratio: -5.24

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 449700

Ebitda: -96.8 million

Market Capitalization: 3.6 billion

Links: